C4 Therapeutics (CCCC) Income from Continuing Operations (2019 - 2026)
C4 Therapeutics (CCCC) recorded quarterly Income from Continuing Operations of 25129000.0 in Q1 2026, down 23.39% quarter-over-quarter from 20365000.0 in Q4 2025, and up 4.53% on a YoY basis from 24039452.59 in Q1 2025.
C4 Therapeutics (CCCC) Income from Continuing Operations (2019 - 2026) Analysis & Trends
C4 Therapeutics' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 25129000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 4.53% year-over-year to 25129000.0; the TTM figure through Mar 2026 stood at 103680000.0 (changed 0.39% YoY), while the FY2025 annual figure was 104994000.0, changed 0.31% from the prior year.
- Income from Continuing Operations was 25129000.0 for Q1 2026 at C4 Therapeutics, down from 20365000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 17716000.0 in Q2 2024 to a low of 37185000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 29144411.76 across 5 years, with a median of 28361000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations tumbled 137.48% in 2022, then soared 50.68% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 37185000.0 in 2022, then increased by 6.53% to 34757000.0 in 2023, then increased by 0.53% to 34573000.0 in 2024, then soared by 41.1% to 20365000.0 in 2025, then slipped by 23.39% to 25129000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 25129000.0 (Q1 2026), 20365000.0 (Q4 2025), and 32166000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | C4 Therapeutics | 520.69 Mn | 285.02 Mn | - | -25.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.13 Mn |
| Dec 31, 2025 | -20.37 Mn |
| Sep 30, 2025 | -32.17 Mn |
| Jun 30, 2025 | -26.02 Mn |
| Mar 31, 2025 | -26.32 Mn |
| Dec 31, 2024 | -34.57 Mn |
| Sep 30, 2024 | -24.67 Mn |
| Jun 30, 2024 | -17.72 Mn |
| Mar 31, 2024 | -28.36 Mn |
| Dec 31, 2023 | -34.76 Mn |
| Sep 30, 2023 | -27.04 Mn |
| Jun 30, 2023 | -35.92 Mn |
| Mar 31, 2023 | -34.78 Mn |
| Dec 31, 2022 | -37.19 Mn |
| Sep 30, 2022 | -31.96 Mn |
| Jun 30, 2022 | -26.88 Mn |
| Mar 31, 2022 | -31.62 Mn |
| Dec 31, 2021 | -15.66 Mn |
| Sep 30, 2021 | -24.68 Mn |
| Jun 30, 2021 | -22.58 Mn |